LOXL2 and carcinoma of esophagus: Notably, this study also reported that overexpression of the LOXL2/L2ΔE13 variant and decreased acetylation of aldolase A at K13 residue (one of the deacetylating targets of LOXL2) served as predictors of poor clinical behaviour in oesophageal cancer patients [16].